Platelet function, blood coagulation and fibrinolysis were studied in 13 patients with myelofibrosis. The main abnormalities were impaired ADP-release and abnormal platelet aggregation with collagen. The delay period was prolonged to a degree varied from a few minutes to indefinitely. Platelet aggregation with ADP was impaired in 5 cases, while adrenaline-induced aggregation was abolished in 7 other patients. Spontaneous changes in the aggregation patterns were also observed. The bleeding time and clot retraction were normal. The platelet factor 3 availability was also normal, except in one case. Blood coagulation and fibrinolysis showed variable mild abnormalities. In one case a low-grade chronic disseminated intravascular coagulation was suspected, while a mild hypercoagulable state was present in other cases. The possible role of platelet function and of blood coagulation abnormalities in the interpretation of haemorrhage and thrombosis in myelofibrosis is discussed.

Keywords:
Blood coagulation, Fibrinolysis, Myelofibrosis, Platelet function
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.